Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Compound Embryonic Bovine Liver Extract Tablets in type 2 diabetes mellitus with nonalcoholic fatty liver disease
ChiCTR-TRC-09000404Phase 4Completed
- Sponsor
- Sun Yat-sen Memorial Hospital
- Start
- Feb 2009
- Modality
- Small Molecules, Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 4, open-label trial of compound embryonic bovine liver extract in metabolic dysfunction-associated steatotic liver disease (MASLD) and type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Sun Yat-sen Memorial Hospital. Primary endpoint: Improvement of fatty liver. Started Feb 2009; status: completed.
02
Drugs
compound embryonic bovine liver extract
03
Conditions
metabolic dysfunction-associated steatotic liver disease (MASLD)type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on ChiCTR-TRC-09000404.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-TRC-09000404.